Vasculitis associated with all trans retinoic acid (ATRA) in a case with acute promyelocytic leukemia

Leuk Lymphoma. 2003 Mar;44(3):547-8. doi: 10.1080/1042819021000055101.

Abstract

All trans retinoic acid is the drug of choice in the treatment of acute promyelocytic leukemia. But this drug has some side effects, some of which may be life-threatening. Retinoic acid syndrome is the most frequent and dangerous side effect of this differentiation inducing agent. Other side effects include Sweet's syndrome, vasculitis, hypercalcemia, bone marrow necrosis and fibrosis, thromboembolic events, erythema nodosum, granulomatous proliferation and some pulmonary complications. Here, we report vasculitis in a case with APL treated with ATRA and review the literature.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Anti-Inflammatory Agents / therapeutic use
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Fever / chemically induced
  • Humans
  • Leukemia, Promyelocytic, Acute / complications
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Male
  • Methylprednisolone / therapeutic use
  • Remission Induction
  • Tretinoin / administration & dosage
  • Tretinoin / adverse effects*
  • Vasculitis / chemically induced*
  • Vasculitis / drug therapy

Substances

  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Tretinoin
  • Methylprednisolone